Cryosection pathology is essential for intraoperative diagnosis of diffuse midline gliomas (DMGs), but often requires re-sampling for an accurate assessment. Here, the authors develop CryoAID, an AI-augmented framework for rapid and accurate molecular outcome prediction during surgery for DMG, reducing re-biopsy rates in clinical cohorts.
